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A B S T R A C T   
Introduction: In the phase II ATLANTIC study, durvalumab provided durable responses with acceptable toler-
ability in heavily pretreated patients with advanced NSCLC, across three independent patient cohorts defined by 
EGFR/ALK status and tumour PD-L1 expression. Preliminary overall survival (OS) data were encouraging. We 
now report final OS and updated safety data. 
Methods: Patients with advanced NSCLC with disease progression following ≥2 previous systemic regimens 
received durvalumab 10 mg/kg every 2 weeks. The primary endpoint was objective response rate among pa-
tients with increased PD-L1 expression (defined as ≥25 % or ≥90 % of tumour cells [TCs], cohort-dependent). 
Secondary endpoints included OS and safety. 
Results: 444 patients received durvalumab: 111 in Cohort 1 (EGFR+/ALK+), 265 in Cohort 2 (EGFR−/ALK−), 
and 68 in Cohort 3 (EGFR−/ALK−; TC ≥ 90 %). Median (95 % CI) OS was 13.3 months (6.3–24.5) in patients 
with EGFR+/ALK+ NSCLC with TC ≥ 25 %, 10.9 months (8.6–13.6) in patients with EGFR–/ALK– NSCLC with 
TC ≥ 25 %, and 13.2 months (5.9–not reached) in patients with EGFR–/ALK– NSCLC with TC ≥ 90 %. Median 
(95 % CI) OS was slightly shorter in patients with TC  <  25 % (9.9 months [4.2–13.3] in patients with EGFR 
+/ALK+ NSCLC and 9.3 months [5.9–10.8] in those with EGFR–/ALK– NSCLC). Treatment-related adverse 
events of special interest occurred with similar incidences as reported previously. 
Conclusions: After additional follow-up, final OS data remain encouraging across all cohorts, further supporting 
the clinical activity of durvalumab in patients with heavily pretreated advanced NSCLC, including those with 
EGFR+/ALK+ tumours. There were no new safety signals.   
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Treatment for advanced non-small cell lung cancer (NSCLC) has 
improved considerably since the introduction of immune checkpoint 
inhibitors targeting the programmed cell death-1 (PD-1)/programmed 
cell death ligand-1 (PD-L1) pathway [1]. However, the clinical benefit 
of anti-PD-1/PD-L1 agents in patients with EGFR mutations or ALK 
receptor tyrosine kinase (ALK) rearrangements (EGFR+/ALK+) is not 
clear; moreover, there are few effective options for patients with ad-
vanced NSCLC who progress after two systemic treatment regimens, 
including those with EGFR−/ALK− tumours. 
Durvalumab is a selective, high-affinity, PD-L1 blocking antibody 
that is approved for patients with unresectable, stage III NSCLC whose 
disease has not progressed following platinum-based chemor-
adiotherapy. 
The phase II ATLANTIC study (NCT02087423) evaluated third- and 
later-line durvalumab monotherapy across three independent NSCLC 
patient cohorts defined by EGFR/ALK status and tumour cell (TC) PD-L1 
expression. The final analysis of the primary endpoint, objective re-
sponse rate (ORR), has been previously reported (data cut-off [DCO] 3 
June 2016) [2]. Consistent with other durvalumab studies [3] and 
meta-analyses [4,5] in advanced NSCLC, the ORR was increased in 
patients with higher levels of tumour PD-L1 expression. Preliminary 
overall survival (OS) data were encouraging although the maturity was 
low, particularly in Cohort 1 (EGFR+/ALK+) and Cohort 3 (EGFR−/ 
ALK−; TC ≥ 90 %), and the median OS had not been reached in 
Cohort 3 [2]. 
Here, with a later DCO of 7 November 2017, we report final OS and 
updated safety results from the ATLANTIC study. 
2. Methods 
2.1. Study design and patients 
ATLANTIC was a phase II, open-label, single-arm, multicentre study 
of durvalumab in patients with stage IIIB/IV NSCLC that recurred or 
progressed following ≥2 systemic treatments, including one platinum- 
based regimen and, if indicated, tyrosine kinase inhibitor therapy. Full 
inclusion and exclusion criteria are described elsewhere [2]. 
Originally, ATLANTIC enrolled all patients, irrespective of PD-L1 
expression; however, following the availability of a validated PD-L1 
diagnostic, the protocol was amended to include only patients with 
TC ≥ 25 % membrane staining for PD-L1 per central assessment of 
recent or archival samples using the VENTANA PD-L1 (SP263) Assay. A 
further protocol amendment added a cohort of patients with TC ≥ 90 % 
membrane staining for PD-L1. Thus, patients were allocated to three 
independent cohorts; patients in Cohort 1 had EGFR+/ALK+ NSCLC 
and Cohorts 2 and 3 had EGFR−/ALK− NSCLC. Cohort 3 comprised 
patients with TC ≥ 90 %. Enrolment into Cohorts 2 and 3 was se-
quential, whereas enrolment into Cohort 1 continued throughout the 
study. 
2.2. Treatment and study endpoints 
Patients were treated with durvalumab 10 mg/kg intravenously 
every 2 weeks until disease progression, unacceptable toxicity, or for up 
to 12 months. Patients who achieved and maintained disease control 
(ie, complete response, partial response, or stable disease) through to 
the end of the initial 12-month treatment period entered follow-up and 
were offered retreatment on evidence of disease progression. The pri-
mary endpoint was ORR in patients with measurable disease at base-
line, per independent central review (ICR), and with TC ≥ 25 % 
(Cohorts 1 and 2) or ≥ 90 % (Cohort 3). Secondary endpoints have 
been outlined previously [2] and included OS (time from first dose until 
death due to any cause) and safety and tolerability. ATLANTIC was 
undertaken in accordance with the ethical principles of the Declaration 
of Helsinki and the International Council on Harmonisation guidelines 
on Good Clinical Practice. The study protocol, including this final OS 
analysis, was approved by the institutional review boards of all parti-
cipating centres. All patients provided written informed consent. 
2.3. Statistical analysis 
OS was assessed by the Kaplan-Meier product-limit method in the 
full analysis set (all treated patients who had a baseline tumour as-
sessment and measurable disease at baseline according to investigator 
assessment). Safety data, including adverse events (AEs) considered by 
the investigator to be possibly related to study treatment (hereafter 
referred to as treatment-related AEs [TRAEs]), and treatment-related 
AEs of special interest (AESIs) on the basis of their potential immune 
cause (in addition to infusion/hypersensitivity reactions), were sum-
marised in the safety analysis set (all patients who received at least one 
dose of durvalumab and had post-dose data) and graded using the 
National Cancer Institute Common Terminology Criteria for Adverse 
Events v4.03. 
Data underlying the findings described in this manuscript 
may be obtained in accordance with AstraZeneca’s data sharing 
policy described at https://astrazenecagrouptrials.pharmacm.com/ST/ 
Submission/Disclosure. 
3. Results 
3.1. Patients and treatment 
Between 25 February 2014 and 28 December 2015, 444 patients 
were enrolled and received durvalumab: 111, 265, and 68 in Cohorts 1, 
2, and 3, respectively (Supplementary Fig. 1). In Cohorts 1 and 2, 38 
and 167 patients were enrolled under the original protocol (irrespective 
of PD-L1 expression) [2]. The full analysis set included 111, 264, and 67 
patients in Cohorts 1, 2, and 3, respectively: in Cohort 1, 77 and 30 
patients had TC ≥ 25 % and TC  <  25 % (4 patients had unknown or 
missing PD-L1 expression); in Cohort 2, 149 and 94 patients had 
TC ≥ 25 % and TC  <  25 % (21 patients had unknown PD-L1 expres-
sion); 67 patients in Cohort 3 had TC ≥ 90 % (one patient had TC 70 % 
and a protocol deviation was reported). The primary endpoint of ORR 
was reported previously and the analysis included all treated patients 
with measurable disease at baseline per ICR (Supplementary Fig. 1) [2]. 
Baseline characteristics were previously reported [2]. Patients had re-
ceived a median (range) of 3.0 (2–11), 3.0 (2–9), and 2.0 (2–5) previous 
anticancer regimens in Cohorts 1, 2, and 3, respectively. At the 7 No-
vember 2017 DCO, the median (range) actual treatment duration ex-
cluding dose delays was 12.0 (2–53), 16.1 (1–62), and 25.9 (2–52) 
weeks in Cohorts 1, 2, and 3, respectively. 
3.2. Final overall survival 
At DCO, 328 (73.9 %) of 444 patients across the study had died 
(safety analysis set). Most deaths (306; 93.3 %) were solely due to 
disease progression. 
Patients with higher PD-L1 expression (TC ≥ 25 % and ≥90 %) had 
numerically longer median OS than those with TC  <  25 %, regardless 
of EGFR/ALK status (Fig. 1). Median (95 % confidence interval [CI]) OS 
in Cohort 1 (EGFR+/ALK+) was 13.3 (6.3–24.5) months in TC ≥ 25 % 
patients and 9.9 (4.2–13.3) months in TC  <  25 %. In Cohort 2 
(EGFR−/ALK−), median OS was 10.9 (8.6–13.6) months in TC ≥ 25 % 
patients and 9.3 (5.9–10.8) months in TC  <  25 % patients, and in 
Cohort 3 (EGFR−/ALK−; TC ≥ 90 %) it was 13.2 (5.9–not reached) 
months. Similarly, 12- and 24-month OS rates were increased in pa-
tients with higher PD-L1 expression, regardless of EGFR/ALK status 
(Fig. 1). 
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Fig. 1. Final overall survival by cohort. 
Abbreviations: ALK, ALK receptor tyrosine kinase; NR, not reached; OS, overall survival; PD-L1, programmed cell death ligand-1; TC, tumour cell. 
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An exploratory post-hoc analysis of TC ≥ 25 % patients in Cohort 1 
separated into subgroups with EGFR+ or ALK+ NSCLC showed 
numerically longer median OS in the EGFR+ subgroup (16.1 months 
[95 % CI 6.2–33.2]) compared with the ALK+ subgroup (6.3 months 
[0.9–not reached]). Similarly, the 12-month OS rate was higher in pa-
tients with EGFR+ NSCLC versus those with ALK+ NSCLC 
(Supplementary Fig. 2). 
3.3. Safety and tolerability 
Grade 3/4 TRAEs occurred in 42 (9.5 %) of 444 patients and 
treatment-related serious AEs occurred in 28 (6.3 %) of patients 
(Table 1). TRAEs leading to treatment discontinuation occurred in 10 
(2.3 %) patients. There were no deaths due to TRAEs before the start of 
subsequent therapy although, as previously reported [2], there was a 
treatment-related death due to pneumonitis after the start of sub-
sequent EGFR tyrosine kinase inhibitor therapy. 
Overall, 139 (31.3 %) of 444 patients had treatment-related AESIs; 
29 (26.1 %) in Cohort 1, 76 (28.7 %) in Cohort 2, and 34 (50.0 %) in 
Cohort 3 (Table 1). The most common treatment-related AESIs were 
dermatitis (37 patients [8.3 %]), hypothyroidism (36 [8.1 %]), rash (32 
[7.2 %]), diarrhoea (27 [6.1 %]), and hyperthyroidism (24 [5.4 %]). 
The most common grade 3 treatment-related AESIs were hepatic la-
boratory parameters reported as AEs (5 patients [1.1 %]), pneumonitis 
(4 [0.9 %]), diarrhoea (3 [0.7 %]), and infusion reactions (3 [0.7 %]). 
There were no grade 4/5 treatment-related AESIs before the start of 
subsequent therapy at the time of analysis. 
4. Discussion 
The mature final OS data from the ATLANTIC study are encoura-
ging, with durvalumab showing clinical activity across subsets of clin-
ical interest in a heavily pretreated patient population. Patients with 
higher tumour PD-L1 expression had numerically longer median OS, 
irrespective of EGFR/ALK status, although the OS in patients with 
TC  <  25 % was also promising. The final OS results in Cohorts 1 and 2, 
including the median OS and 12-month OS rates, were consistent with 
the results reported at the earlier DCO [2]. The OS results observed in 
ATLANTIC were also similar to those seen with other single-agent anti- 
PD-1/PD-L1 therapies in patients with advanced NSCLC treated in the 
third-line and later setting in single-arm trials [6,7]. 
No new safety signals were evident at the later DCO. As previously 
reported [2], Cohort 3 had a higher incidence of treatment-related 
AESIs than Cohorts 1 and 2. AESIs were manageable with standard 
guidelines and most were grade 1/2 in severity. These results remain 
consistent with other anti-PD-1/PD-L1 therapies in pretreated advanced 
NSCLC [7–10]. 
Retrospective analyses have suggested that EGFR−/ALK− tumours 
respond better than EGFR+/ALK+ tumours to anti-PD-1/PD-L1 
therapy [11–13]. Although uncontrolled, ATLANTIC represents the 
largest prospective analysis of treatment with anti-PD-1/PD-L1 therapy 
in patients with EGFR+/ALK+ NSCLC (n = 111) to date. Among 
pretreated (including prior tyrosine kinase inhibitor therapy) patients 
with advanced EGFR+/ALK+ NSCLC (TC ≥ 25 %), the median OS was 
13.3 months with a 24-month OS rate of 40.7 %, which was greater 
Table 1 
Summary of treatment-related adverse events and frequency of treatment-related adverse events of special interest (safety analysis set).          
Cohort 1, EGFR+/ALK+ 
(n = 111) 
Cohort 2, EGFR−/ALK− a 
(n = 265) 
Cohort 3, EGFR−/ALK− a;  
TC ≥ 90% (n = 68) 
Any TRAE, n (%) 53 (48) 157 (59) 46 (68) 
Grade 3 or 4 TRAEs 6 (5) 23 (9) 13 (19) 
TRAEs leading to death 0 0c 0 
Treatment-related serious AEs 5 (5) 14 (5) 9 (13) 
TRAEs leading to discontinuation 1 (1) 8 (3) 1 (1)          
Grade 1/2 Grade 3b Grade 1/2 Grade 3b Grade 1/2 Grade 3b  
Any treatment-related AESI, n (%) 27 (24) 2 (2) 67 (25) 9 (3) 25 (37) 9 (13) 
Dermatitis 6 (5) 0 20 (8) 1 (< 1) 10 (15) 0 
Hypothyroidism 10 (9) 0 17 (6) 0 9 (13) 0 
Rash 6 (5) 0 16 (6) 0 9 (13) 1 (1) 
Diarrhoea 4 (4) 0 17 (6) 1 (< 1) 3 (4) 2 (3) 
Hyperthyroidism 7 (6) 0 11 (4) 0 6 (9) 0 
Pneumonitis 1 (1) 1 (1) 4 (2) 3 (1) 3 (4) 0 
Hepatic laboratory parameters reported as AEs 1 (1) 0 3 (1) 2 (1) 2 (3) 3 (4) 
Infusion reaction/hypersensitivity 0 1 (1) 3 (1) 1 (< 1) 1 (1) 1 (1) 
Adrenal insufficiency 0 0 1 (< 1) 1 (< 1) 1 (1) 1 (1) 
Thyroid laboratory parameters reported as AEs (decreased thyroid activity) 1 (1) 0 3 (1) 0 0 0 
Renal laboratory investigations reported as AEs 1 (1) 0 2 (1) 0 1 (1) 0 
Pancreatic laboratory investigations reported as AEs 1 (1) 0 0 0 2 (3) 0 
Thyroid laboratory parameters reported as AEs (increased thyroid activity) 1 (1) 0 1 (< 1) 0 0 0 
Colitis 0 0 0 0 1 (1) 0 
Hepatitis 0 0 1 (< 1) 0 0 0 
Hypophystitis 0 0 0 0 0 1 (1) 
Nephritis 0 0 1 (< 1) 0 0 0 
Thyroiditis 1 (1) 0 2 (1) 0 0 0 
AESIs are grouped Medical Dictionary for Regulatory Activities v20.0 preferred terms. Includes all AEs considered by the investigator to be possibly related to study 
treatment with an onset date on or after the date of first dose or pretreatment AEs that increase in severity on or after the date of first durvalumab dose up to and 
including 90 days following the date of last dose of study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurred 
first). Each patient has been represented once with the maximum reported Common Terminology Criteria for Adverse Events v4.03 grade for each AESI. If a patient 
has multiple events within an AESI, then the maximum grade across those events is counted for that preferred term. 
Abbreviations: AE, adverse event; AESI, adverse event of special interest; ALK, ALK receptor tyrosine kinase; TC, tumour cell; TRAE, treatment-related adverse event. 
a Includes patients with unknown EGFR/ALK status. 
b There were no grade 4 or 5 treatment-related AESIs at the time of analysis. 
c There was one treatment-related pneumonitis event with an outcome of death that is not included in this table because the AE began after the start of subsequent 
therapy (the patient developed pneumonitis 65 days after discontinuing durvalumab because of disease progression and 2 days after starting subsequent therapy with 
erlotinib) [2].  
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than that observed in patients with TC ≥ 25 % EGFR−/ALK− tumours 
(median OS of 10.9 months and 24-month OS of 24.2 %). Furthermore, 
when focusing on the subgroup of patients with EGFR+ NSCLC 
(TC ≥ 25 %), excluding those with ALK+ NSCLC, the median OS was 
extended to 16.1 months. The phase III IMpower150 study also showed 
promising OS results with PD-L1 blockade in patients with EGFR+ 
chemotherapy-naïve metastatic NSCLC, albeit in a combination therapy 
setting rather than with anti-PD-L1 monotherapy. In a subgroup of 
patients with sensitising EGFR mutations, atezolizumab in combination 
with bevacizumab plus chemotherapy provided OS benefit compared 
with bevacizumab plus chemotherapy alone [14]. In the present ana-
lysis of ATLANTIC, as observed at the earlier DCO [2], median OS was 
short in patients with TC ≥ 25 % ALK+ NSCLC (6.3 months), although 
this was a very small subgroup of only 12 patients meaning that no 
conclusions for this subgroup can be made from this study. Further 
clinical investigation in EGFR+/ALK+ NSCLC using prospectively 
designed controlled studies is warranted to understand the role of 
durvalumab in this population. 
In conclusion, final OS data from the ATLANTIC study continue to 
support the clinical activity of durvalumab in patients with heavily 
pretreated advanced NSCLC, including those with EGFR+/ALK+ tu-
mours. 
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